Genetic Syndromes Associated With Renal Cell Carcinoma - A Review

Azeem, Kateřina; Kollárová, Helena; Horáková, D; Magnusková, Silvie; Janout, Vladimí­r

doi:10.5507/bp.2011.029

Cited by 8 publications

(7 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Each of the known genes for RCC is involved in oxygen, iron, and energy or nutrient-sensing pathways in a way or another (Azeem et al, 2011;Jonasch et al, 2012;Linehan and Ricketts, 2013). In a recent epidemiologic study from Northern Europe, Haggstrom et al found that high levels of several metabolic factors, both separately and combined, were associated with an increased risk of RCC.…”

Section: Discussionmentioning

confidence: 99%

Metabolic Syndrome Prevalence in Renal Cell Cancer Patients

Bulut¹,

Aktaş²,

Erkmen³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Metabolic Syndrome Prevalence in Renal Cell Cancer Patients

Bulut¹,

Aktaş²,

Erkmen³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…Unfortunately, approximately 30% of RCC patients have metastatic lesions detected at initial diagnosis . The morbidity and mortality of RCC have still been growing up during the past several years . Due to its resistance to radiation‐ and chemo‐therapy and immunotherapy, surgical resection remains the unique curative treatment for RCC .…”

Section: Introductionmentioning

confidence: 99%

“…3 The morbidity and mortality of RCC have still been growing up during the past several years. 4 Due to its resistance to radiation-and chemo-therapy and immunotherapy, surgical resection remains the unique curative treatment for RCC. 5,6 Although tyrosine kinase inhibitor (TKI)-based antiangiogenic therapy is standard treatment for advanced RCC (aRCC) or metastatic RCC (mRCC) and improves the prognosis of patients, its effect remains limited because of drug resistance.…”

Section: Introductionmentioning

confidence: 99%

DNA‐methylation‐mediated repression of miR‐766‐3p promotes cell proliferation via targeting SF2 expression in renal cell carcinoma

Chen

Xue

Zhang

et al. 2017

Intl Journal of Cancer

View full text Add to dashboard Cite

Aberrant expression of microRNA (miRNA) emerges as an important role in a wide range of human malignances, and further identification as well as validation of the change of these endogenous non-protein-coding transcripts is warranted. Here, we identify a novel epigenetic regulation of miR-766-3p and investigate its biological function as well as clinical significance in renal cell carcinoma (RCC). Bisulfate analysis elucidates that the promoter of miR-766-3p is highly methylated in RCC tissues compared to non-tumorous tissues. Notably, the downregulation of miR-766-3p is obviously associated with clinical stage and worse prognosis in RCC patients. Upregulated miR-766-3p attenuates cell-cycle progression via targeting SF2 expression and additional SF2/P-AKT/P-ERK signaling pathway. Moreover, high level of SF2, as a novel oncoprotein in RCC, was significantly associated with poor survival in a large cohort of RCC specimens. Taken together, our study presents a road map for the prediction and validation of miR-766-3p/SF2 axis and thus imparts a therapeutic way for further RCC progression.

show abstract

“…265731 individuals were diagnosed with renal caner and 113315 individuals died from this type of cancer in 2008 [2], [3]. More seriously, the morbidity and mortality of this type of cancer is still growing [4]. 90–95% of renal cell carcinoma arises from the kidney and the occurrence of tumors is associated with racial and ethnic characteristic [1].…”

Section: Introductionmentioning

confidence: 99%

LncRNAs Expression Signatures of Renal Clear Cell Carcinoma Revealed by Microarray

Yao

Wang

et al. 2012

PLoS ONE

View full text Add to dashboard Cite

BackgroundLong noncoding RNAs (lncRNAs) are an important class of pervasive genes involved in a variety of biological functions. They are aberrantly expressed in many types of cancers. In this study, we described lncRNAs profiles in 6 pairs of human renal clear cell carcinoma (RCCC) and the corresponding adjacent nontumorous tissues (NT) by microarray.Methodology/Principal FindingsWith abundant and varied probes accounting 33,045 LncRNAs in our microarray, the number of lncRNAs that expressed at a certain level could be detected is 17157. From the data we found there were thousands of lncRNAs that differentially expressed (≥2 fold-change) in RCCC tissues compared with NT and 916 lncRNAs differentially expressed in five or more of six RCCC samples. Compared with NT, many lncRNAs were significantly up-regulated or down-regulated in RCCC. Our data showed that down-regulated lncRNAs were more common than up-regulated ones. ENST00000456816, X91348, BC029135, NR_024418 were evaluated by qPCR in sixty-three pairs of RCCC and NT samples. The four lncRNAs were aberrantly expressed in RCCC compared with matched histologically normal renal tissues.Conclusions/SignificanceOur study is the first one to determine genome-wide lncRNAs expression patterns in RCCC by microarray. The results displayed that clusters of lncRNAs were aberrantly expressed in RCCC compared with NT samples, which revealed that lncRNAs differentially expressed in tumor tissues and normal tissues may exert a partial or key role in tumor development. Taken together, this study may provide potential targets for future treatment of RCCC and novel insights into cancer biology.

show abstract

Genetic Syndromes Associated With Renal Cell Carcinoma - A Review

Cited by 8 publications

References 53 publications

Metabolic Syndrome Prevalence in Renal Cell Cancer Patients

Metabolic Syndrome Prevalence in Renal Cell Cancer Patients

DNA‐methylation‐mediated repression of miR‐766‐3p promotes cell proliferation via targeting SF2 expression in renal cell carcinoma

LncRNAs Expression Signatures of Renal Clear Cell Carcinoma Revealed by Microarray

Contact Info

Product

Resources

About